Filtered By:
Source: Circulation
Condition: Thrombosis
This page shows you your search results in order of date.
Order by Relevance | Date
Total 87 results found since Jan 2013.
Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III
CONCLUSIONS: The benefit of LAA occlusion was consistent whether patients were receiving OACs or not. LAA occlusion provides thromboembolism reduction in patients independent of OAC use.PMID:37732457 | DOI:10.1161/CIRCULATIONAHA.122.060315
Source: Circulation - September 21, 2023 Category: Cardiology Authors: Stuart J Connolly Jeff S Healey Emilie P Belley-Cote Kumar Balasubramanian Domenico Paparella Katheryn Brady Wilko Reents Bernhard C Danner P J Devereaux Mukul Sharma Chinthanie Ramasundarahettige Salim Yusuf Richard P Whitlock Source Type: research
Shorter Door-to-Needle Times Are Associated With Better Outcomes After Intravenous Thrombolytic Therapy and Endovascular Thrombectomy for Acute Ischemic Stroke
CONCLUSIONS: Among older patients with stroke treated with either IVT only or IVT+EVT, shorter DTN times are associated with better long-term functional outcomes and lower mortality. These findings support further efforts to accelerate thrombolytic administration in all eligible patients, including EVT candidates.PMID:37199147 | DOI:10.1161/CIRCULATIONAHA.123.064053
Source: Circulation - May 18, 2023 Category: Cardiology Authors: Shumei Man Nicole Solomon Brian Mac Grory Brooke Alhanti Ken Uchino Jeffrey L Saver Eric E Smith Ying Xian Deepak L Bhatt Lee H Schwamm Muhammad Shazam Hussain Gregg C Fonarow Source Type: research
Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial
CONCLUSIONS: The study was terminated prematurely after enrollment of 32% of planned accrual because of recruitment challenges and lower-than-expected event rate. Rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis did not appear to reduce a composite end point of venous and arterial thrombotic events, hospitalization, and death.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04508023.PMID:37154020 | DOI:10.1161/CIRCULATIONAHA.123.063901
Source: Circulation - May 8, 2023 Category: Cardiology Authors: Gregory Piazza Alex C Spyropoulos Judith Hsia Mark Goldin William J Towner Alan S Go Todd M Bull Stephen Weng Concetta Lipardi Elliot S Barnathan Marc P Bonaca PREVENT-HD Investigators Source Type: research
Pharmacology and Clinical Development of Factor XI Inhibitors
This article reviews the rationale, pharmacology, results of medium or small phase 2 studies, and future perspectives of drugs inhibiting FXI.PMID:36913497 | DOI:10.1161/CIRCULATIONAHA.122.062353
Source: Circulation - March 13, 2023 Category: Cardiology Authors: Antonio Greco Claudio Laudani Marco Spagnolo Federica Agnello Denise Cristiana Faro Simone Finocchiaro Marco Legnazzi Maria Sara Mauro Placido Maria Mazzone Giovanni Occhipinti Carla Rochira Lorenzo Scalia Davide Capodanno Source Type: research
Aspirin vs. Clopidogrel for Chronic Maintenance Monotherapy after Percutaneous Coronary Intervention: the HOST-EXAM Extended Study
Conclusions: During an extended follow-up of over 5 years after randomization, clopidogrel monotherapy as compared with aspirin monotherapy was associated with lower rates of the composite net clinical outcome in patients without clinical events for 12±6 months after PCI with DES.PMID:36342475 | DOI:10.1161/CIRCULATIONAHA.122.062770
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Jeehoon Kang Kyung Woo Park Huijin Lee Doyeon Hwang Han-Mo Yang Seung-Woon Rha Jang-Whan Bae Nam Ho Lee Seung Ho Hur Jung-Kyu Han Eun-Seok Shin Bon-Kwon Koo Hyo-Soo Kim Source Type: research
A Randomized Controlled Trial Comparing Apixaban to the Vitamin K-antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 study
Conclusions: In this randomized trial comparing apixaban and VKA in patients with AF on hemodialysis with long follow-up, no differences were observed in safety or efficacy outcomes. Even on oral anticoagulation, patients with AF on hemodialysis remain at high risk of cardiovascular events. Larger randomized trials are needed to determine the optimal anticoagulation regimen for patients with AF on hemodialysis. Clinical Trial Registration: EudraCT No. 2015-005503-84, NCT02933697.PMID:36335915 | DOI:10.1161/CIRCULATIONAHA.122.062779
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Holger Reinecke Christiane Engelbertz Rupert Bauersachs G ünter Breithardt Hans-Herbert Echterhoff Joachim Ger β Karl Georg Haeusler Bernd Hewing Joachim Hoyer Sabine Juergensmeyer Thomas Klingenheben Guido Knapp Lars Christian Rump Hans Schmidt-Guertle Source Type: research
